生长抑素受体显像能够特异性的定位肿瘤所致骨软化症（TIO）的致病肿瘤，仍有部分病例为假阴性结果。本项目旨在应用免疫组化技术和蛋白质印迹法研究TIO的致病肿瘤组织的Ki-67指数、SSTR2和FGF-23、微血管密度的表达状态及其相互关系；与TIO患者血清FGF-23及其他各种生化指标、骨代谢、多种分子影像结果，如68Ga-DOTATATE和18F-FDG PET显像等的相关性分析；并比较其在不同显像结果组的差异；从而明确SSTR2和FGF-23在TIO的发病机制中的重要作用，及其与肿瘤恶性程度、复发及预后的相关性。从分子水平解释分子影像呈现不同结果的原因及其临床意义，进一步提高分子影像技术对TIO的临床诊断效能。

Somatostatin receptor imaging is able to locate the causative tumor of tumor-induced osteomalacia(TIO), there are still some cases of false negative results.The aim of the study is to detect the expression of Ki-67, FGF-23,SSTR2 and microvessel density in the causative tumours of patients by immunohistochemistry and Western blotting. Correlations between these influencing factors, such as serum FGF-23 level and other various biochemical markers, bone metabolism , expression of Ki-67, FGF-23,SSTR2 and microvessel density in the causative tumours, and 68Ga-DOTATATE and 18F-FDG PET/CT imaging will be analyzed,and the divergence of these affecting factors in every different Imaging results group will be compared. Then the study shows that FGF-23 and SSTR2 play important roles in the pathogenesis of TIO and some correlation between them and the degree of malignancy, recurrence and prognosis. This study attempts to explain the reason of different results in molecular imaging and its clinical significance at the molecular level, and further improve the diagnostic efficiency of TIO.